Thrombosis research最新文献

英文中文

IF 3.4 3区医学 Q1 HEMATOLOGY

Thrombosis research

Pub Date : 2026-01-01

引用次数: 0

IF 3.4 3区医学 Q1 HEMATOLOGY

Thrombosis research

Pub Date : 2026-01-01

引用次数: 0

IF 3.4 3区医学 Q1 HEMATOLOGY

Thrombosis research

Pub Date : 2026-01-01

引用次数: 0

IF 3.4 3区医学 Q1 HEMATOLOGY

Thrombosis research

Pub Date : 2026-01-01

引用次数: 0

Factors associated with venous and arterial thrombosis in patients with Systemic Lupus Erythematosus: A systematic review and meta-analysis 系统性红斑狼疮患者静脉和动脉血栓形成的相关因素：系统回顾和荟萃分析。

IF 3.4 3区医学 Q1 HEMATOLOGY

Thrombosis research

Pub Date : 2025-12-29 DOI: 10.1016/j.thromres.2025.109572

Xiaoling Shui , Yuqiong Cao , Yuhong He , Shan Zeng , Na Ye , Mao Ma

Background

Thrombosis, encompassing both venous thromboembolism (VTE) and arterial thrombotic events, represents a leading cause of mortality in patients with Systemic Lupus Erythematosus (SLE). A comprehensive evaluation of risk factors specific to each thrombotic type remains lacking.

Objective

To systematically identify and compare risk factors for venous and arterial thrombosis in SLE patients through a meta-analysis.

Methods

We systematically searched PubMed, Web of Science, Embase, Cochrane Library, CNKI, and Wanfang Data from inception to August 2025. Cohort studies (prospective or retrospective) and case-control studies reporting multivariable-adjusted associations between risk factors and thrombotic events in SLE were included. Two researchers independently performed study selection, data extraction, and quality assessment using the Newcastle-Ottawa Scale. Pooled odds ratios (ORs) with 95 % confidence intervals (CIs) were calculated using random-effects models.

Results

Analysis of 25 studies (13,290 patients) identified distinct risk factor profiles. For venous thrombosis, lupus anticoagulant showed the strongest association (OR 6.17, 95 % CI 2.77–13.76), followed by anti-β2-glycoprotein I IgA (OR 4.77, 95 % CI 3.08–7.39). Antiphospholipid syndrome demonstrated an exceptionally high risk (OR 44.72, 95 % CI 9.93–201.34). Elevated D-dimer was a specific venous thrombosis predictor (OR 1.35, 95 % CI 1.22–1.49). For arterial thrombosis, traditional cardiovascular risk factors predominated, including hypertension (OR 3.39, 95 % CI 2.38–4.83) and obesity (OR 3.17, 95 % CI 1.50–6.66). Disease-related factors such as high SLEDAI scores (OR 1.11, 95 % CI 1.05–1.16) and renal insufficiency (OR 2.38, 95 % CI 1.42–4.00) were associated with increased thrombotic risk.

Conclusion

Thrombosis in SLE exhibits distinct risk factor patterns between venous and arterial events. Venous thrombosis is strongly driven by antiphospholipid antibodies, while arterial events are predominantly associated with traditional cardiovascular risk factors. This review identifies and distinguishes key risk factors for venous and arterial thrombosis in SLE. These findings highlight the necessity for thrombotic type-specific risk assessment and provide an evidence base to inform the future development of targeted preventive strategies.

背景：血栓形成，包括静脉血栓栓塞（VTE）和动脉血栓事件，是系统性红斑狼疮（SLE）患者死亡的主要原因。对每种血栓形成类型的危险因素的综合评估仍然缺乏。目的：通过荟萃分析系统地识别和比较SLE患者静脉和动脉血栓形成的危险因素。方法：系统检索PubMed、Web of Science、Embase、Cochrane Library、CNKI、万方数据，检索时间为建站至2025年8月。队列研究（前瞻性或回顾性）和病例对照研究报告了SLE中危险因素与血栓形成事件之间的多变量调整相关性。两名研究人员使用纽卡斯尔-渥太华量表独立进行研究选择、数据提取和质量评估。采用随机效应模型计算95%置信区间（ci）的合并优势比（ORs）。结果：对25项研究（13290例患者）的分析确定了不同的风险因素。对于静脉血栓形成，狼疮抗凝剂的相关性最强（OR 6.17, 95% CI 2.77 ~ 13.76），其次是抗β2-糖蛋白I IgA （OR 4.77, 95% CI 3.08 ~ 7.39）。抗磷脂综合征表现出异常高的风险（OR 44.72, 95% CI 9.93-201.34）。升高的d -二聚体是特定的静脉血栓形成预测因子（OR 1.35, 95% CI 1.22-1.49）。对于动脉血栓，传统的心血管危险因素占主导地位，包括高血压（OR 3.39, 95% CI 2.38-4.83）和肥胖（OR 3.17, 95% CI 1.50-6.66）。疾病相关因素，如高SLEDAI评分（OR 1.11, 95% CI 1.05-1.16）和肾功能不全（OR 2.38, 95% CI 1.42-4.00）与血栓形成风险增加相关。结论：SLE血栓形成在静脉和动脉事件之间表现出不同的危险因素模式。静脉血栓形成是由抗磷脂抗体强烈驱动的，而动脉事件主要与传统的心血管危险因素相关。这篇综述确定并区分了SLE中静脉和动脉血栓形成的关键危险因素。这些发现强调了血栓形成特定类型风险评估的必要性，并为未来制定有针对性的预防策略提供了证据基础。

{"title":"Factors associated with venous and arterial thrombosis in patients with Systemic Lupus Erythematosus: A systematic review and meta-analysis","authors":"Xiaoling Shui , Yuqiong Cao , Yuhong He , Shan Zeng , Na Ye , Mao Ma","doi":"10.1016/j.thromres.2025.109572","DOIUrl":"10.1016/j.thromres.2025.109572","url":null,"abstract":"<div><h3>Background</h3><div>Thrombosis, encompassing both venous thromboembolism (VTE) and arterial thrombotic events, represents a leading cause of mortality in patients with Systemic Lupus Erythematosus (SLE). A comprehensive evaluation of risk factors specific to each thrombotic type remains lacking.</div></div><div><h3>Objective</h3><div>To systematically identify and compare risk factors for venous and arterial thrombosis in SLE patients through a meta-analysis.</div></div><div><h3>Methods</h3><div>We systematically searched PubMed, Web of Science, Embase, Cochrane Library, CNKI, and Wanfang Data from inception to August 2025. Cohort studies (prospective or retrospective) and case-control studies reporting multivariable-adjusted associations between risk factors and thrombotic events in SLE were included. Two researchers independently performed study selection, data extraction, and quality assessment using the Newcastle-Ottawa Scale. Pooled odds ratios (ORs) with 95 % confidence intervals (CIs) were calculated using random-effects models.</div></div><div><h3>Results</h3><div>Analysis of 25 studies (13,290 patients) identified distinct risk factor profiles. For venous thrombosis, lupus anticoagulant showed the strongest association (OR 6.17, 95 % CI 2.77–13.76), followed by anti-β2-glycoprotein I IgA (OR 4.77, 95 % CI 3.08–7.39). Antiphospholipid syndrome demonstrated an exceptionally high risk (OR 44.72, 95 % CI 9.93–201.34). Elevated D-dimer was a specific venous thrombosis predictor (OR 1.35, 95 % CI 1.22–1.49). For arterial thrombosis, traditional cardiovascular risk factors predominated, including hypertension (OR 3.39, 95 % CI 2.38–4.83) and obesity (OR 3.17, 95 % CI 1.50–6.66). Disease-related factors such as high SLEDAI scores (OR 1.11, 95 % CI 1.05–1.16) and renal insufficiency (OR 2.38, 95 % CI 1.42–4.00) were associated with increased thrombotic risk.</div></div><div><h3>Conclusion</h3><div>Thrombosis in SLE exhibits distinct risk factor patterns between venous and arterial events. Venous thrombosis is strongly driven by antiphospholipid antibodies, while arterial events are predominantly associated with traditional cardiovascular risk factors. This review identifies and distinguishes key risk factors for venous and arterial thrombosis in SLE. These findings highlight the necessity for thrombotic type-specific risk assessment and provide an evidence base to inform the future development of targeted preventive strategies.</div></div>","PeriodicalId":23064,"journal":{"name":"Thrombosis research","volume":"258 ","pages":"Article 109572"},"PeriodicalIF":3.4,"publicationDate":"2025-12-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145864789","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Bluetooth enabled point-of-care INR device validation for warfarin management 蓝牙启用点护理INR设备验证华法林管理。

IF 3.4 3区医学 Q1 HEMATOLOGY

Thrombosis research

Pub Date : 2025-12-22 DOI: 10.1016/j.thromres.2025.109570

Robert D. McBane II , Jennifer Lutz , Carlee O'Connor , Anna Kramer , Michael Luker , David Hodge , Colleen S. Thomas , Harold J. Hellweg

Objective

Systems employing point-of-care (POC) INR monitoring with patient self-testing require test accuracy, data integrity, patient compliance, and prompt two-way communication for high quality warfarin management. With a goal of validating a POC Bluetooth capable device for prompt INR transfer to electronic medical record, two POC INR devices were compared against an internal plasma INR reference.

Methods

A multicenter study (February 14, 2023 – August 29, 2023) comparing concordance of two commercially available POC devices, Vantus and CoaguChek XS (Pro and Plus), against a plasma INR reference, was pursued among warfarin treated patients. Appropriateness of dosing decisions were assessed for each device.

Results

Across three Mayo Clinic sites, 151 warfarin treated patients agreed to participate. Atrial fibrillation (41.7 %), venous thromboembolism (33.1 %) and heart valve prosthesis (19.9 %) were common indications with target INR range 2.0–3.0 in 89 %. For the CoaguChek devices, 86.1 % of values fell within 0.4 INR units compared with plasma INR referent (CoaguChek - plasma INR correlation R² = 0.95). For the Vantus device, 88.7 % of values fell within 0.4 INR units of plasma INR values (Vantus – plasma INR correlation R² = 0.96). Mean (± standard deviation) deviation from plasma INR was 0.2 ± 0.3 for CoaguChek compared to 0.1 ± 0.2 for Vantus (p < 0.001). Using the plasma INR as the gold standard for dosing recommendations, appropriate dosing recommendations were similar between devices: CoaguChek 83.4 % vs Vantus 82.7 %.

Conclusions

Compared to a plasma referent, INR values obtained from the CoaguChek and Vantus devices exhibited strong correlation with plasma INR values without systemic bias.

目的：采用患者自检的护理点（POC） INR监测系统要求检测准确性、数据完整性、患者依从性和及时的双向沟通，以实现高质量的华法林管理。为了验证具有POC蓝牙功能的设备是否能够及时将INR传输到电子医疗记录，我们将两个POC INR设备与内部等离子体INR参考进行了比较。方法：一项多中心研究（2023年2月14日- 2023年8月29日）在华法林治疗的患者中比较了两种市售POC装置Vantus和CoaguChek XS （Pro和Plus）与血浆INR参考的一致性。评估每个装置的给药决定的适当性。结果：在梅奥诊所的三个地点，151名接受华法林治疗的患者同意参与。房颤（41.7%）、静脉血栓栓塞（33.1%）和心脏瓣膜置换术（19.9%）是常见的适应症，89%的患者目标INR在2.0-3.0之间。对于CoaguChek装置，与血浆INR参考值相比，86.1%的值下降在0.4 INR单位以内（CoaguChek -血浆INR相关R2 = 0.95）。对于Vantus装置，88.7%的数值落在血浆INR值的0.4 INR单位内（Vantus -血浆INR相关R2 = 0.96）。CoaguChek与血浆INR的平均（±标准差）偏差为0.2±0.3，而Vantus为0.1±0.2 (p)。结论：与血浆参考物相比，CoaguChek和Vantus装置获得的INR值与血浆INR值具有很强的相关性，无系统偏倚。

{"title":"Bluetooth enabled point-of-care INR device validation for warfarin management","authors":"Robert D. McBane II , Jennifer Lutz , Carlee O'Connor , Anna Kramer , Michael Luker , David Hodge , Colleen S. Thomas , Harold J. Hellweg","doi":"10.1016/j.thromres.2025.109570","DOIUrl":"10.1016/j.thromres.2025.109570","url":null,"abstract":"<div><h3>Objective</h3><div>Systems employing point-of-care (POC) INR monitoring with patient self-testing require test accuracy, data integrity, patient compliance, and prompt two-way communication for high quality warfarin management. With a goal of validating a POC Bluetooth capable device for prompt INR transfer to electronic medical record, two POC INR devices were compared against an internal plasma INR reference.</div></div><div><h3>Methods</h3><div>A multicenter study (February 14, 2023 – August 29, 2023) comparing concordance of two commercially available POC devices, Vantus and CoaguChek XS (Pro and Plus), against a plasma INR reference, was pursued among warfarin treated patients. Appropriateness of dosing decisions were assessed for each device.</div></div><div><h3>Results</h3><div>Across three Mayo Clinic sites, 151 warfarin treated patients agreed to participate. Atrial fibrillation (41.7 %), venous thromboembolism (33.1 %) and heart valve prosthesis (19.9 %) were common indications with target INR range 2.0–3.0 in 89 %. For the CoaguChek devices, 86.1 % of values fell within 0.4 INR units compared with plasma INR referent (CoaguChek - plasma INR correlation R<sup>2</sup> = 0.95). For the Vantus device, 88.7 % of values fell within 0.4 INR units of plasma INR values (Vantus – plasma INR correlation R<sup>2</sup> = 0.96). Mean (± standard deviation) deviation from plasma INR was 0.2 ± 0.3 for CoaguChek compared to 0.1 ± 0.2 for Vantus (<em>p</em> < 0.001). Using the plasma INR as the gold standard for dosing recommendations, appropriate dosing recommendations were similar between devices: CoaguChek 83.4 % vs Vantus 82.7 %.</div></div><div><h3>Conclusions</h3><div>Compared to a plasma referent, INR values obtained from the CoaguChek and Vantus devices exhibited strong correlation with plasma INR values without systemic bias.</div></div>","PeriodicalId":23064,"journal":{"name":"Thrombosis research","volume":"258 ","pages":"Article 109570"},"PeriodicalIF":3.4,"publicationDate":"2025-12-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145864826","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Qualitative comparison of perioperative anticoagulation management guidelines across US institutions 美国各机构围手术期抗凝管理指南的定性比较。

IF 3.4 3区医学 Q1 HEMATOLOGY

Thrombosis research

Pub Date : 2025-12-20 DOI: 10.1016/j.thromres.2025.109569

Ishan J. Tatake , Rishabh Singh , Caroline Cromwell , Brianna Bakow , Jacob Cogan , Manila Gaddh , Radhika Gangaraju , Ming Y. Lim , Colleen T. Morton , Andrew M. Peseski , Rachel P. Rosovsky , Kimberley Youkhana , Lisa Baumann Kreuziger

Background

The indications for anticoagulation and the number of patients on anticoagulation is rising. Accordingly, adverse drug events related to anticoagulation use are on the rise and represents an opportunity for improvement in patient safety. About 15–20 % of patients on anticoagulation undergo invasive procedures. Perioperative management of anticoagulation requires balancing competing risks of thrombosis and bleeding. Clear, concise and evidence-based institutional guidelines are essential for providers to make individualized treatment decisions and to improve patient safety.

Study design and methods

We qualitatively compared perioperative anticoagulation management guidelines from 11 US academic institutions. We also conducted a survey to evaluate how healthcare providers interpret perioperative anticoagulation management when different wording is used to convey recommendations.

Results

Institution-specific guidelines of the 11 US academic institutions varied in the management of perioperative anticoagulation and used different language to convey recommendations. In the survey, there was >90 % consensus amongst healthcare providers on the appropriate management of perioperative rivaroxaban and apixaban when the guidelines used the wording of “no dose day -X” which is used in the American College of Chest Physicians (CHEST) 2022 guidelines. Additionally, institution-specific guidelines were not available in 24.2 % of survey respondents.

Conclusions

This study demonstrates that institutions do not always have perioperative guidelines for anticoagulation management and when they do, there is variation in recommendations despite published international guidelines for perioperative management of anticoagulation. The language used to convey recommendations is important to standardizing perioperative anticoagulation management. These represent areas for further quality improvement and patient safety through anticoagulation stewardship.

背景：抗凝的适应症和抗凝患者的数量正在上升。因此，与抗凝使用相关的药物不良事件呈上升趋势，这为改善患者安全提供了机会。约15- 20%接受抗凝治疗的患者接受有创手术。围手术期抗凝治疗需要平衡血栓和出血的竞争风险。清晰、简明和基于证据的机构指南对于提供者做出个性化治疗决策和改善患者安全至关重要。研究设计和方法：我们对美国11家学术机构的围手术期抗凝治疗指南进行定性比较。我们还进行了一项调查，以评估当使用不同的措辞来传达建议时，医疗保健提供者如何解释围手术期抗凝管理。结果：美国11家学术机构的机构指南在围手术期抗凝治疗管理方面存在差异，并且使用了不同的语言来传达建议。在调查中，当指南使用美国胸科医师学会（Chest） 2022指南中使用的“无剂量日-X”措辞时，医疗保健提供者对利伐沙班和阿哌沙班围手术期的适当管理达成了约90%的共识。此外，24.2%的调查对象没有特定机构的指导方针。结论：本研究表明，各机构并不总是有围手术期抗凝管理指南，即使有，尽管已公布的国际抗凝围手术期管理指南，建议也存在差异。表达建议的语言对规范围手术期抗凝管理很重要。这些都代表了通过抗凝管理进一步提高质量和患者安全的领域。

{"title":"Qualitative comparison of perioperative anticoagulation management guidelines across US institutions","authors":"Ishan J. Tatake , Rishabh Singh , Caroline Cromwell , Brianna Bakow , Jacob Cogan , Manila Gaddh , Radhika Gangaraju , Ming Y. Lim , Colleen T. Morton , Andrew M. Peseski , Rachel P. Rosovsky , Kimberley Youkhana , Lisa Baumann Kreuziger","doi":"10.1016/j.thromres.2025.109569","DOIUrl":"10.1016/j.thromres.2025.109569","url":null,"abstract":"<div><h3>Background</h3><div>The indications for anticoagulation and the number of patients on anticoagulation is rising. Accordingly, adverse drug events related to anticoagulation use are on the rise and represents an opportunity for improvement in patient safety. About 15–20 % of patients on anticoagulation undergo invasive procedures. Perioperative management of anticoagulation requires balancing competing risks of thrombosis and bleeding. Clear, concise and evidence-based institutional guidelines are essential for providers to make individualized treatment decisions and to improve patient safety.</div></div><div><h3>Study design and methods</h3><div>We qualitatively compared perioperative anticoagulation management guidelines from 11 US academic institutions. We also conducted a survey to evaluate how healthcare providers interpret perioperative anticoagulation management when different wording is used to convey recommendations.</div></div><div><h3>Results</h3><div>Institution-specific guidelines of the 11 US academic institutions varied in the management of perioperative anticoagulation and used different language to convey recommendations. In the survey, there was >90 % consensus amongst healthcare providers on the appropriate management of perioperative rivaroxaban and apixaban when the guidelines used the wording of “no dose day -X” which is used in the American College of Chest Physicians (CHEST) 2022 guidelines. Additionally, institution-specific guidelines were not available in 24.2 % of survey respondents.</div></div><div><h3>Conclusions</h3><div>This study demonstrates that institutions do not always have perioperative guidelines for anticoagulation management and when they do, there is variation in recommendations despite published international guidelines for perioperative management of anticoagulation. The language used to convey recommendations is important to standardizing perioperative anticoagulation management. These represent areas for further quality improvement and patient safety through anticoagulation stewardship.</div></div>","PeriodicalId":23064,"journal":{"name":"Thrombosis research","volume":"257 ","pages":"Article 109569"},"PeriodicalIF":3.4,"publicationDate":"2025-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145828424","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Aptamer-based monitorization and therapeutic applications of blood coagulation cascade disorders: A systematic review 基于适配体的凝血级联障碍监测和治疗应用：系统综述。

IF 3.4 3区医学 Q1 HEMATOLOGY

Thrombosis research

Pub Date : 2025-12-19 DOI: 10.1016/j.thromres.2025.109566

Okan Yılmaz , Beyza Nur Yılmaz , Neslihan Betül Kandilcik , Zeynep Sebla Yiğit , Mediha Esra Altuntop Yayla

Hemostasis is a complex physiological process that prevents blood loss following vascular injury via the blood coagulation cascade. The coagulation cascade is a highly controlled stepwise process that establishes clotting only at the site of bleeding, when needed. Recently, aptamers have been employed not only in the fields of biosensors and diagnostics, but also in molecular imaging, therapeutics, and drug delivery systems. The present article highlights recent developments in aptamer-based biomedical systems for the diagnosis and treatment of blood coagulation cascade disorders. Specifically, aptasensors for thrombin detection and aptamer-based medical imaging of thrombi were addressed as diagnostic tools for coagulation cascade disorders. Additionally, the use of aptamers as pharmaceutical agents and aptamer-targeted drug delivery systems were highlighted as part of the treatment. In summary, this is a valuable compilation in this emerging field that focuses on aptamer-based applications for monitoring and treatment of blood coagulation cascade disorders.

止血是一个复杂的生理过程，通过血凝级联防止血管损伤后的失血。凝血级联是一个高度控制的逐步过程，在需要时仅在出血部位建立凝血。近年来，适体不仅应用于生物传感器和诊断领域，还应用于分子成像、治疗和药物输送系统。本文重点介绍了用于诊断和治疗凝血级联疾病的适配体生物医学系统的最新进展。具体来说，用于凝血酶检测的适配体传感器和基于适配体的血栓医学成像被认为是凝血级联疾病的诊断工具。此外，适体作为药物制剂和适体靶向药物递送系统的使用被强调为治疗的一部分。总之，这是一个有价值的汇编在这个新兴领域，重点是基于适配体的应用监测和治疗凝血级联障碍。

{"title":"Aptamer-based monitorization and therapeutic applications of blood coagulation cascade disorders: A systematic review","authors":"Okan Yılmaz , Beyza Nur Yılmaz , Neslihan Betül Kandilcik , Zeynep Sebla Yiğit , Mediha Esra Altuntop Yayla","doi":"10.1016/j.thromres.2025.109566","DOIUrl":"10.1016/j.thromres.2025.109566","url":null,"abstract":"<div><div>Hemostasis is a complex physiological process that prevents blood loss following vascular injury <em>via</em> the blood coagulation cascade. The coagulation cascade is a highly controlled stepwise process that establishes clotting only at the site of bleeding, when needed. Recently, aptamers have been employed not only in the fields of biosensors and diagnostics, but also in molecular imaging, therapeutics, and drug delivery systems. The present article highlights recent developments in aptamer-based biomedical systems for the diagnosis and treatment of blood coagulation cascade disorders. Specifically, aptasensors for thrombin detection and aptamer-based medical imaging of thrombi were addressed as diagnostic tools for coagulation cascade disorders. Additionally, the use of aptamers as pharmaceutical agents and aptamer-targeted drug delivery systems were highlighted as part of the treatment. In summary, this is a valuable compilation in this emerging field that focuses on aptamer-based applications for monitoring and treatment of blood coagulation cascade disorders.</div></div>","PeriodicalId":23064,"journal":{"name":"Thrombosis research","volume":"258 ","pages":"Article 109566"},"PeriodicalIF":3.4,"publicationDate":"2025-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145864797","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Letter to “Erythrocyte rheology is altered in haemophilia patients with advanced arthropathy. A case-control study” 致“血友病合并晚期关节病患者红细胞流变学改变”的信。病例对照研究”。

IF 3.4 3区医学 Q1 HEMATOLOGY

Thrombosis research

Pub Date : 2025-12-18 DOI: 10.1016/j.thromres.2025.109568

XiaoMei Wang , SongQian Yang

引用次数: 0

Impact of ABO blood group on global coagulation assays ABO血型对整体凝血试验的影响

IF 3.4 3区医学 Q1 HEMATOLOGY

Thrombosis research

Pub Date : 2025-12-17 DOI: 10.1016/j.thromres.2025.109567

Tengyi Cai , Vincent Lu , Julie Wang , Mani Suleiman , Prahlad Ho , Hui Yin Lim

引用次数: 0

首页上一页

下一页尾页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

Thrombosis research

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀